| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Therasense, Inc. |
| 1360 South Loop Road, Alameda, CA 94502 * (510) 749-5400 |
| Business Description | The company develops and sells easy glucose self-monitoring systems that dramatically reduce the pain of testing for people with diabetes. |
|
Filing Information IPO has been | |||
| To Trade As | THER (NASNTL) | Industry | Manufacturing (SIC 3841) |
| Type of Stock Offered | Common Shares | Filing Date | 10/11/2000 |
| Domestic Shares Filed | 0 | Filing Price | - - |
| Foreign Shares Filed | 0 | Offering Amount | $75,000,000 |
| Company Shares | 0 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Bear, Stearns & Co. Inc. | Lead Manager | (212) 272-4850 |
| Lehman Brothers Incorporated | Co-manager | (212) 526-8100 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/1997 | 12/31/1998 | 12/31/1999 | 6/30/1999 | 6/30/2000 | ||
| Revenues | - | - | 0.000 | 0.060 | 0.000 | 0.000 | 0.511 |
| Income from Oper. | - | - | -1.680 | -4.806 | -13.144 | -5.115 | -15.413 |
| Net Income | - | - | -1.517 | -4.664 | -13.058 | -4.953 | -15.059 |
| E.P.S | - | - | -1.660 | -2.310 | -4.320 | -1.790 | -8.030 |
| Revenue Growth (%) | - | - | - | -100.000 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -11.79 | -4.88 | -17.03 | ||||
| Cash Flow - Inv. | -3.32 | 0.49 | -1.36 | ||||
| Cash Flow - Fin. | 6.00 | 3.37 | 44.09 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/2000 | Financial Ratios | ||||
| Total Assets | 43.81 | Current Assets | 38.82 | Current Ratio | 4.49 |
| Total Liab. | 76.50 | Current Liab. | 8.65 | Debt Ratio | 174.62% |
| Total Equity | -32.69 | Working Cap. | 30.17 | Debt to Equity Ratio | - |
| Cash | 29.62 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for additional sales and marketing efforts and research and development as well as for working capital and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm | Brobeck, Phleger & Harrison |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| InterWest Partners | 17.39 | |
| Brentwood Venture Capital | 14.00 | |
| E. Heller & Co. | 12.43 | |
| Delphi Ventures | 11.25 | |
| Lehman Brothers | 7.95 | |
| Sequoia Capital | 7.13 | |
| MedVentures Associates | 5.85 | |
| EGI-Fund Investors, L.L.C. | 5.01 | |
| Note: represents ownership of 5% or more prior to the offering. | ||